Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL

Exclusion Criteria

• •Concomitant history of cardiac, hepatic, neurologic, nephrologic, psychiatric, autoimmune and additional oncological diseases affecting physiological functions
• •Life expectancy \<2 months
• •Hepatitis B, Hepatitis C, Human immunodeficiency virus infection
• •Before CAR-T (ISIKOK-19 ©) cell infusion
• •1. Systemic steroid treatments, tyrosine kinase inhibitors, hydroxyurea, short-acting cytotoxic drugs should be stopped 72 hours before.
• •2. 1 week ago, vincristine, 6-mercaptopurine, 6-thioguanine, methotrexate (if \<25 mg / m\^2), cytosine arabinoside (if \<100 mg / m\^2), asparaginase and intrathecal treatments should be stopped.
• •3. 2 weeks ago, salvage treatments (chemotherapy drugs other than lymphodepletion as part of the protocol, clofarabine, cytosine arabinoside (if\> 100 mg / m\^2), anthracyclines, methotrexate (if ≥25 mg / m\^2), drugs used for graft versus host disease, long-acting growth factors, vincristine, immunomodulatory drugs should be stopped.
• •4. Radiotherapy taken outside the central nervous system should be stopped 2 weeks prior.
• •5. Any systemic treatment with pegylated asparaginase and donor lymphocyte infusion should be stopped 4 weeks prior.
• •6. Anti-t cell therapies containing T cell lysis or toxic antibodies should be stopped 8 weeks before.
• •7. Radiotherapy for the central nervous system should be stopped 8 weeks ago.
• •8. Less than 3 months after stem cell transplantation
• •9. Below 60% in tissue biopsies and / or CD19 expression in tumor cells by flow cytometric analysis in bone marrow is below 85%
• •Allergic to drugs that are used at any stage of treatment
• •Having received experimental drug treatment in the last month
• •Previously entered a cellular therapy and / or a gene therapy program
• •Disapproval of the storage of tissues and cells
• •Isolated disease that occurs outside the bone
• •A genetic disease associated with concomitant bone marrow failure
• •Active Grade 2-4 acute or diffuse chronic graft versus host disease
• •Being pregnant or breastfeeding
• •Disapproval the treatment
• •Patients with slow CAR-T cell expansion (the cell number is not doubled in 48 hours) and with less than 10% expression of CAR-T cells during production, \< 60% cytotoxicity results in in-vitro study (i.e, patients whose product is inappropriate)